AI is emerging as a structural tailwind for the Life Science industry, and in turn, Life Sciences real estate. These tailwinds are impacting demand on multiple fronts: leasing data shows AI-native tenants are filling traditional biotech spaces due to the sectors’ similar resource needs, while at the same time, AI capabilities are compressing drug discovery timelines and costs, reigniting interest from venture and pharma investment in wet-lab space.
Our Q2 2026 REIT Cap Rate Perspective Summary Report offers a more detailed analysis of how AI is fueling the Life Sciences recovery by reshaping tenant demand, along with our perspective on what this means for capital deployment ahead.
